Harvard MD: The Truth About Peptides And Longevity Medicine

Harvard MD: The Peptide Boom Is Here.. But Is Medicine Ready?In this episode of Return on Health, Niko and Miguel speak with Dr. Anand Vinjamoori, Harvard Medical School and Harvard Business School trained physician, former founding Chief Medical Officer at Modern Age, advisor to Superpower, and founder of Next Generation Medicine.Together, they discuss why longevity medicine is booming while many companies still struggle to build sustainable businesses, why peptides may become one of the next major waves in health optimization, and why the future of biomarkers will likely require a much more individualized and data-driven approach.This episode covers:The peptide boom and why it mattersWhy longevity businesses often failWhat biomarkers can and cannot tell usDr. Anand explains why the current medical evidence system may be too slow for the next generation of therapies, how real-world data and patient registries could help close the evidence gap, and why biomarkers should be used with nuance rather than treated as absolute truth. He also shares his view on overhyped interventions, the role of exercise, and the cultural differences between American optimization culture and European lifestyle rhythms.Key topicsLongevity medicine and market timingThe business challenges behind longevity clinicsCustomer acquisition and why messaging mattersThe rise of peptides in health optimizationEvidence gaps, real-world data, and patient registriesPersonalized medicine and individual risk assessmentBiomarkers, multi-omics, and biological individualityWhy HBA1c can be overinterpretedExercise as one of the strongest health interventionsCold plunges and the problem of overapplied hormesisEuropean lifestyle culture vs. American optimization cultureChapters00:00 The Longevity Paradox01:03 Building Modern Age and the Early Longevity Market05:04 Personal Motivations Behind Longevity Medicine07:57 What Patients Actually Want From Longevity Care11:39 Why Many Longevity Businesses Struggle15:12 How Customer Preferences Have Changed18:21 Peptides as the Next Big Wave19:07 Peptides, Regulation, and Medical Experimentation24:24 The Evidence Gap in Peptide Use30:58 Why Medicine Needs Better Risk Assessment36:59 Biomarkers and Biological Ground Truth44:20 Multi-Omics and the Future of Measurement48:35 Which Biomarkers Are Useful — And Which Are Noise?52:42 Culture, Lifestyle, and Health Optimization55:45 Lightning Round: Metrics, Interventions, and Healthcare ReformGuestDr. Anand VinjamooriHarvard Medical School and Harvard Business School trained physician, former founding Chief Medical Officer at Modern Age, advisor to Superpower, and founder of Next Generation Medicine.Guest linksLinkedIn: https://www.linkedin.com/in/vinjamoori/Next Generation Medicine: https://www.nextgenerationmedicine.co/Superpower: https://www.linkedin.com/company/superpower/posts/?feedView=allListen nowReturn on Health is available wherever you get your podcasts.If you enjoyed this episode, leaving a 5-star rating on Spotify helps us bring more honest conversations about health, longevity, and medicine to more people.